Floatz logo

cgt4255

ERBB2 Gene Amplification

Cogent Biosciences, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the ERBB2 Gene Amplification cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 2BB
Cetuximab
SWOG Cancer Research Network
Phase 2B
Irinotecan
SWOG Cancer Research Network
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 2B
Everolimus
M.D. Anderson Cancer Center
Phase 1CC

View all 11 →

Same molecule, other indications

cgt4255 is also rated in:

Advanced Solid Tumor, AdultDormant
CC
Indicative ·
43 / 100
View asset →
HER2 positive breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
HER2 OverexpressionDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →